HALIFAX,
April 16, 2013 /CNW/ - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic technology
and solutions, announced today that it is strengthening the
Company's sales and distribution channel in the United States by working directly with
Cardinal Health and VWR International to sell and distribute the
Reveal G3 Rapid HIV-1 Antibody Test. Previously, MedMira's
agent American Health Partners maintained these relationships on
behalf of the Company and effective today this contract has been
concluded.
"Working directly with Cardinal and VWR to
support their sales teams and their customers is the type of
relationship we look for under our partnership strategy," said
Hermes Chan, CEO, MedMira Inc.
"They have been our long term distribution partners and they know
our product well. We fully expect to expand our product line
with them in the near future."
Chan added, "With this change, we are looking
ahead to the launch of our next generation rapid HIV test to meet
the growing demand based on the new U.S. Preventative Services Task
Force (USPSTF) guidelines which recommend routine HIV screening for
all people aged 15-65 and all pregnant women in the United States. We will follow this
up with the launch of the new US Army funded rapid tests, Multiplo
HBc/HIV/HCV and Reveal HBsAg. Working directly with our key
distributors will better position us to capitalize on these
opportunities with a significantly increased profit margin."
In advance of these product launches, MedMira
will set up a sales and marketing office dedicated to supporting
the growing business opportunities in the US. In the interim,
the Company has engaged a third party logistics provider, My Care
Solution, to handle the import and warehousing of the product.
About MedMira
MedMira is a leading developer and manufacturer
of flow-through rapid diagnostics. The company's tests provide
hospitals, labs, clinics and individuals with reliable, rapid
diagnosis for diseases such as HIV and hepatitis C in just three
minutes. The company's tests are sold under the Reveal®, Multiplo™
and Miriad brands in global markets. MedMira's rapid flow-through
HIV test is the only one in the world to achieve regulatory
approvals in Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MEDMIRA INC.
